Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash from Financing Activities: 2013-2024

Historic Cash from Financing Activities for Neurogene (NGNE) over the last 12 years, with Dec 2024 value amounting to $184.1 million.

  • Neurogene's Cash from Financing Activities rose 7312.21% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $199.8 million, marking a year-over-year increase of 126.30%. This contributed to the annual value of $184.1 million for FY2024, which is 99.03% up from last year.
  • Neurogene's Cash from Financing Activities amounted to $184.1 million in FY2024, which was up 99.03% from $92.5 million recorded in FY2023.
  • Neurogene's 5-year Cash from Financing Activities high stood at $184.1 million for FY2024, and its period low was $732,000 during FY2021.
  • Moreover, its 3-year median value for Cash from Financing Activities was $92.5 million (2023), whereas its average is $114.4 million.
  • In the last 5 years, Neurogene's Cash from Financing Activities tumbled by 99.05% in 2021 and then skyrocketed by 8,988.93% in 2022.
  • Over the past 5 years, Neurogene's Cash from Financing Activities (Yearly) stood at $77.1 million in 2020, then tumbled by 99.05% to $732,000 in 2021, then spiked by 8,988.93% to $66.5 million in 2022, then spiked by 39.01% to $92.5 million in 2023, then surged by 99.03% to $184.1 million in 2024.